Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NBM-BMX in Advanced Solid Tumors or Newly Diagnosed Glioblastoma
NCT06012695Phase 2Recruiting
- Sponsor
- Novelwise Pharmaceutical Corporation
- Start
- Aug 2023
- Primary completion
- May 2028
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of NBM-BMX in solid tumor, glioblastoma (GBM), sponsored by Novelwise Pharmaceutical Corporation. Started Aug 2023; status: recruiting.
02
Drugs
NBM-BMX
03
Conditions
solid tumorglioblastoma (GBM)
Beyond the preview
Go deeper on NCT06012695.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06012695.